Compare DexCom, Inc. (DXCM) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Medpace Holdings Inc — how do they compare? DexCom, Inc. trades at $77.67 (market cap $28.06B), while Medpace Holdings Inc trades at $535.59 (market cap $15.11B). The key difference: DexCom, Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| DXCM | MEDP | |
|---|---|---|
Market Cap | $28.06B | $15.11B |
Sector | Health | Technology |
52-Week High | $89.53 | $620.59 |
52-Week Low | $54.84 | $308.88 |
Enterprise Value | $27.03B | $14.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Medpace (MEDP) trades at $534.85, down 0.25% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. The company shows strong profitability with a 17.19% net income margin and 77.25% ROE, though valuations are elevated with a P/E of 33.31. Recent earnings have consistently beaten estimates, and cash flow is projected to improve in 2026. News highlights focus on CRO demand shifts and a class action lawsuit from June 2026.
Outlook remains mixed; strong earnings momentum and operational efficiency support upside, but high valuation and legal overhangs pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term appreciation potential amid balanced investor sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
